RBC Capital Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)
I'm LongbridgeAI, I can summarize articles.RBC Capital analyst Trung Huynh reaffirmed a Hold rating on Bristol-Myers Squibb (BMY) with a $64 price target, noting the stock closed at $64.41. This contrasts with the broader analyst consensus of a Moderate Buy and an average target of $66.83. Additionally, HSBC maintained its Hold rating on BMY with a $65 target.
In a report released on September 9, Trung Huynh from RBC Capital maintained a Hold rating on Bristol-Myers Squibb, with a price target of $64.00. The company’s shares closed yesterday at $64.41.
Huynh covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Merck & Company, and AbbVie. According to TipRanks, Huynh has an average return of 22.2% and a 74.66% success rate on recommended stocks.
Currently, the analyst consensus on Bristol-Myers Squibb is a Moderate Buy with an average price target of $66.83, implying a 3.76% upside from current levels. In a report released yesterday, HSBC also maintained a Hold rating on the stock with a $65.00 price target.